8-ethyl-7-(4-heptyl)-1-methyl-3,7-dihydro-1H-purine-2,6-dione | 488706-07-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-ethyl-7-(4-heptyl)-1-methyl-3,7-dihydro-1H-purine-2,6-dione
• 英文别名: 8-ethyl-7-heptan-4-yl-1-methyl-3H-purine-2,6-dione
• CAS: 488706-07-6
• 化学式: C₁₅H₂₄N₄O₂
• 分子量: 292.381
• InChiKey: ZSTHMAUVSXFSGQ-UHFFFAOYSA-N

物化性质

• 熔点：
  152.5-153 °C
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-ethyl-7-(4-heptyl)-1-methyl-3,7-dihydro-1H-purine-2,6-dione 在 吡啶 、 lithium aluminium tetrahydride 、 copper diacetate 、 4 A molecular sieve 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 3-(4-Chloro-phenyl)-8-ethyl-1-methyl-7-(1-propyl-butyl)-1,2,3,7-tetrahydro-purin-6-one
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor₁ Receptor Antagonists

  摘要：

  A growing body of evidence suggests that CRF1, receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF, receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF, antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.

  DOI：

  10.1021/jm049787k
• 作为产物：
  描述：

  4-庚基甲烷磺酸盐 在 potassium carbonate 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 8-ethyl-7-(4-heptyl)-1-methyl-3,7-dihydro-1H-purine-2,6-dione
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor₁ Receptor Antagonists

  摘要：

  A growing body of evidence suggests that CRF1, receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF, receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF, antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.

  DOI：

  10.1021/jm049787k

文献信息

• 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
  申请人：——

  公开号：US20030119831A1

  公开（公告）日：2003-06-26

  Compounds provided herein are 3,7-dihydro-purine-2,6-dione derivatives of Formula (I): 1 Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis or hypoglycemia.

  本文提供的化合物是Formula (I)的3,7-二氢嘌呤-2,6-二酮衍生物。这些化合物特别适用作为CRF受体配体，因此在治疗各种神经相关疾病方面特别有用，如情感障碍、焦虑和抑郁症、头痛、肠易激综合征、创伤后应激障碍、上核性麻痹、免疫抑制、阿尔茨海默病、胃肠疾病、厌食症或其他进食障碍、药物成瘾、药物或酒精戒断症状、炎症性疾病、心血管或心脏相关疾病、生育问题、人类免疫缺陷病毒感染、出血性应激、肥胖、不孕症、头部和脊髓创伤、癫痫、中风、溃疡、肌萎缩性侧索硬化或低血糖症。
• Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
  申请人：——

  公开号：US20030149059A1

  公开（公告）日：2003-08-07

  Compounds provided herein are novel substituted tetrahydropurinones of Formula (I): 1 Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.

  本文提供的化合物是具有式(I)的新型取代四氢嘌呤酮。这些化合物特别适用作为CRF受体配体，因此在治疗各种神经相关疾病，如情感障碍、焦虑和抑郁症方面具有重要作用。
• US6894045B2
  申请人：——

  公开号：US6894045B2

  公开（公告）日：2005-05-17
• US7098217B2
  申请人：——

  公开号：US7098217B2

  公开（公告）日：2006-08-29
• [EN] 3,7-DIHYDRO-PURINE-2,6-DIONE DERIVATIVES AS CRF RECEPTOR LIGANDS<br/>[FR] DERIVES DE 3,7-DIHYDRO-PURINE-2,6-DIONE UTILISES COMME LIGANDS DU RECEPTEUR DE CRF
  申请人：BRISTOL MYERS SQUIBB PHARMA CO

  公开号：WO2003043637A1

  公开（公告）日：2003-05-30

  Compounds provided herein are 3,7-dihyrdo-purine-2,6-dione derivatives of Formula (I): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis or hypoglycemia.